Thursday 4th November 2021

First take at home COVID-19 antiviral treatments approved for vulnerable adults

Yesterday, the UK’s Medicine and Health products Regulation Agency approved the world’s first ‘take at home’ COVID-19 treatment, Lagevrio – one of two antiviral treatments secured by the UK Government in October.

Read Article

Thursday 21st October 2021

2021 Flu Season - Are you at risk? Are you eligible for the vaccine?

With autumn now firmly upon us, we are facing the onset of the winter flu season. If you have systemic sclerosis you may be at a higher risk if you catch the flu. What can you do to protect yourself?

Read Article

Tuesday 19th October 2021

UPDATED: Breaking News - NICE approve Nintedanib for use in PF-ILD, which includes SSc Interstitial Lung Disease

SRUK are pleased to announce that NICE have approved the use of Nintedanib in treating progressive fibrosing interstitial lung disease (PF-ILD)!

Read Article

Friday 15th October 2021

Stratified Medicine - The Latest SRUK Grant Call

What is stratified medicine? Stratified medicine is also known as personalised medicine and works by dividing patients within the larger group into subgroups by factors that make their condition different.

Read Article

Friday 1st October 2021

Creating Clinical Trials for Children

: Affecting around 200 children in the UK, Juvenile Localised Scleroderma is an incredibly rare condition. Developing new treatments is challenging due to small numbers of patients. Find out how SRUK and Alder Hey are tackling this!

Read Article

Friday 17th September 2021

2021 Virtual Conference Round-Up

A series of talks took place throughout the day, covering areas of research funded by SRUK, advice on symptom management, and discussions about the future. This article offers a brief overview of each talk as a taster, and in the coming months they will be made available online.

Read Article

Thursday 16th September 2021

Living with lung disease: Georgina's story

September is Pulmonary Fibrosis Awareness Month. Pulmonary fibrosis (PF) is also known as interstitial lung disease (ILD) and is the most common form of lung involvement in SSc. This can occur at any time, although early detection often leads to much better outcomes. This is Georgina’s story of living with lung disease, which has a dramatic impact upon her life.

Read Article

Wednesday 1st September 2021

The OCTAVE Study: Scaling up our understanding of vaccine effectiveness in people living with autoimmune conditions

OCTAVE study reveals how effective COVID-19 vaccinations are in immunocompromised participants

Read Article

Thursday 26th August 2021

Just in time! UK approves new COVID-19 treatment for immunocompromised individuals

As OCTAVE study sheds light on the reduced immune response in those with chronic illness, the new antibody treatment from Regeneron and Roche could be of great benefit for those who are immunosuppressed or immunocompromised.

Read Article

Friday 6th August 2021

Utilizing Ultrasound

Dr Victoria Flower was awarded funding by SRUK to research non-invasive methods of skin assessment in scleroderma. Last month, her work was published in The Journal of Rheumatology, discussing the potential use of High Frequency Ultrasound as a more objective and detailed measure of skin involvement in scleroderma.

Read Article